Abstract

Breast cancer (BC) is one of the most heterogeneous diseases. The specific clinical and pathological features of each patient's BC diagnosis determine the response to specific agents and thus the prognosis. There is a great need for personalized management approaches to avoid over- or under-treatment. Recently, a novel method revolutionized the world of cancer research: the clustered regularly interspersed short palindromic repeats (CRISPR)-Cas9, an RNA-programmable system. The advantages of CRISPR Cas9 system mean simple and effective. It is increasingly being used in the field of BC research, including evaluation of the established therapies.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call